根據(jù)一項(xiàng)近期的協(xié)議，Abbott實(shí)驗(yàn)室獲得了將Nephromics公司獲得的的檢測(cè)和監(jiān)測(cè)先兆子癇的兩種蛋白質(zhì)，開(kāi)發(fā)成商業(yè)化產(chǎn)品的全球準(zhǔn)獨(dú)家權(quán)利。，

Abbott打算開(kāi)發(fā)成為檢測(cè)先兆子癇的體外檢測(cè)方法。目前對(duì)這種危及生命的疾病還沒(méi)有特異性的診斷檢測(cè)方法，這種疾病每年都危及許多妊娠婦女。Abbott實(shí)驗(yàn)室診斷測(cè)試與系統(tǒng)開(kāi)發(fā)副總裁William Brow博士解釋說(shuō)：“Abbott的目標(biāo)是開(kāi)發(fā)分娩前檢測(cè)方法，能夠用于對(duì)妊娠并發(fā)癥進(jìn)行早期的危險(xiǎn)分層檢測(cè)。”

Abbott具有研發(fā)內(nèi)分泌和其它激素相關(guān)檢測(cè)方法的歷史；向全球診斷檢測(cè)市場(chǎng)的關(guān)鍵領(lǐng)域提供范圍廣泛的革新設(shè)備系統(tǒng)和檢測(cè)方法。

“Because preeclampsia can strike quickly, potentially causing severe and immediate complications such as seizures and organ failure that threaten both the health of the baby and mother unless pregnancy is induced, early diagnostic tests are needed,” observed David Barch, M.D., medical director, Abbott Diagnostics. “These tests would be developed for use on our premier diagnostic analyzer, the Architect integrated immunoassay and clinical chemistry system.”
Abbott診斷公司的醫(yī)學(xué)主任David Barch說(shuō)：“因?yàn)橄日鬃影B起病迅速，能夠?qū)е聡?yán)重的并發(fā)癥，例如癲癇發(fā)作和器官功能衰竭，在妊娠沒(méi)有開(kāi)始之前就會(huì)危及嬰兒和母親的健康，因此早期診斷檢測(cè)是十分必要的。這些即將研制的檢測(cè)方法，將使用我們公司功能強(qiáng)大的診斷分析儀：Architect綜合免疫分析和臨床化學(xué)系統(tǒng)。”

Abbott to Develop Preeclampsia Test
 
Under a recent agreement, worldwide semi-exclusive rights to commercialize products using patents of Nephromics (Chestnut Hill, MA, USA) related to two proteins for detecting and monitoring preeclampsia have been granted to Abbott Laboratories (Abbott Park, IL, USA).

Abbott intends to develop an in vitro diagnostic test to detect preeclampsia. There is currently no specific diagnostic test for this life-threatening disease that affects many pregnant women each year. “Abbott’s goal is to develop prenatal tests that could be utilized for early risk stratification of pregnancy complications,” explained William Brown, Ph.D., vice president, diagnostic assays and systems development, Abbott Labs.

Abbott has a history of developing endocrine and other hormone-related tests and offers a broad range of innovative instrument systems and tests across key segments of the global diagnostics market. Immunodiagnostics is a core component of the company’s medical products business.

“Because preeclampsia can strike quickly, potentially causing severe and immediate complications such as seizures and organ failure that threaten both the health of the baby and mother unless pregnancy is induced, early diagnostic tests are needed,” observed David Barch, M.D., medical director, Abbott Diagnostics. “These tests would be developed for use on our premier diagnostic analyzer, the Architect integrated immunoassay and clinical chemistry system.”